دورية أكاديمية
A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge.
العنوان: | A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge. |
---|---|
المؤلفون: | Edwards KR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, USA., Malhi H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Schmidt K; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Davis AR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Homad LJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Warner NL; HDT Bio, Seattle, WA, USA., Chhan CB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, USA., Scharffenberger SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Gaffney K; HDT Bio, Seattle, WA, USA., Hinkley T; HDT Bio, Seattle, WA, USA., Potchen NB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, USA., Wang JY; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Institute for Protein Design, University of Washington, Seattle, WA, USA., Price J; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA., Olson J; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA., King NP; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Institute for Protein Design, University of Washington, Seattle, WA, USA., Lund JM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Global Health, University of Washington, Seattle, WA, USA., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Erasmus JH; HDT Bio, Seattle, WA, USA., McGuire AT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. amcguire@fredhutch.org.; Department of Global Health, University of Washington, Seattle, WA, USA. amcguire@fredhutch.org.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. amcguire@fredhutch.org. |
المصدر: | NPJ vaccines [NPJ Vaccines] 2024 Jun 26; Vol. 9 (1), pp. 120. Date of Electronic Publication: 2024 Jun 26. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: [London] : Springer Nature in partnership with the Sealy Center for Vaccine Development, [2016]- |
مستخلص: | Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity and mortality remains an unmet need. EBV is orally transmitted, infecting both B cells and epithelial cells. Several virally encoded proteins are involved in entry. The gH/gL glycoprotein complex is essential for infectivity irrespective of cell type, while gp42 is essential for infection of B cells. gp350 promotes viral attachment by binding to CD21 or CD35 and is the most abundant glycoprotein on the virion. gH/gL, gp42 and gp350, are known targets of neutralizing antibodies and therefore relevant immunogens for vaccine development. Here, we developed and optimized the delivery of several alphavirus-derived replicon RNA (repRNA) vaccine candidates encoding gH/gL, gH/gL/gp42 or gp350 delivered by a cationic nanocarrier termed LION™. The lead candidate, encoding full-length gH/gL, elicited high titers of neutralizing antibodies that persisted for at least 8 months and a vaccine-specific CD8 + T cell response. Transfer of vaccine-elicited IgG protected humanized mice from EBV-driven tumor formation and death following high-dose viral challenge. These data demonstrate that LION/repRNA-gH/gL is an ideal candidate vaccine for preventing EBV infection and/or related malignancies in humans. (© 2024. The Author(s).) |
References: | Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549) Sci Transl Med. 2020 Aug 5;12(555):. (PMID: 32690628) Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2202371119. (PMID: 35917353) Nature. 1992 Mar 26;356(6367):347-50. (PMID: 1312681) Annu Rev Immunol. 2015;33:787-821. (PMID: 25706097) BMJ Open. 2020 Aug 30;10(8):e037505. (PMID: 32868361) Curr Top Microbiol Immunol. 2015;390(Pt 1):211-40. (PMID: 26424648) J Virol. 2000 Mar;74(5):2451-4. (PMID: 10666279) Cell Host Microbe. 2023 Nov 8;31(11):1882-1897.e10. (PMID: 37848029) J Infect Dis. 2016 Sep 1;214(5):762-71. (PMID: 27296848) Adv Exp Med Biol. 2018;1045:477-493. (PMID: 29896681) PLoS Pathog. 2023 Apr 19;19(4):e1011298. (PMID: 37075079) J Clin Microbiol. 1999 Jan;37(1):132-6. (PMID: 9854077) Immunity. 2022 Nov 8;55(11):2135-2148.e6. (PMID: 36306784) Immunol Res. 2015 Feb;61(1-2):117-25. (PMID: 25407647) Cell Rep Med. 2023 Nov 21;4(11):101296. (PMID: 37992686) Nat Commun. 2021 Nov 16;12(1):6624. (PMID: 34785638) Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989) Mol Ther. 2023 Apr 5;31(4):1046-1058. (PMID: 36965482) Proc Natl Acad Sci U S A. 1980 May;77(5):2979-83. (PMID: 6248876) Cell Rep. 2013 Feb 21;3(2):371-85. (PMID: 23416052) J Virol. 2006 Oct;80(19):9444-54. (PMID: 16973550) J Virol. 1996 Aug;70(8):5557-63. (PMID: 8764069) Science. 2022 Jan 21;375(6578):296-301. (PMID: 35025605) Front Immunol. 2021 Oct 08;12:734471. (PMID: 34691042) PLoS Pathog. 2014 Aug 21;10(8):e1004309. (PMID: 25144748) Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50. (PMID: 9653172) Cell. 1987 Jul 17;50(2):203-13. (PMID: 3036369) Immunity. 2024 Mar 12;57(3):559-573.e6. (PMID: 38479361) Blood. 2017 Feb 23;129(8):959-969. (PMID: 28077418) Pathogens. 2013 Mar 14;2(1):153-76. (PMID: 25436886) Mol Ther. 2018 Oct 3;26(10):2507-2522. (PMID: 30078765) J Infect Dis. 2008 Sep 1;198(5):673-82. (PMID: 18627269) Mol Ther. 2023 Aug 2;31(8):2360-2375. (PMID: 37403357) Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8703-E8710. (PMID: 28939750) Cell Rep Med. 2022 Jun 21;3(6):100658. (PMID: 35705092) J Virol. 1982 Jan;41(1):258-64. (PMID: 6177865) Pathogens. 2020 Feb 12;9(2):. (PMID: 32059472) Immunity. 2019 May 21;50(5):1305-1316.e6. (PMID: 30979688) Vaccines (Basel). 2021 Mar 19;9(3):. (PMID: 33808755) J Virol. 2000 Jul;74(14):6324-32. (PMID: 10864642) J Cancer Res Clin Oncol. 2022 Jan;148(1):31-46. (PMID: 34705104) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Cell Rep Med. 2020 Jun 23;1(3):. (PMID: 32724901) PLoS One. 2010 Sep 01;5(9):. (PMID: 20824132) Sci Transl Med. 2022 May 4;14(643):eabf3685. (PMID: 35507671) Immunity. 2018 Apr 17;48(4):799-811.e9. (PMID: 29669253) J Virol. 1998 Jan;72(1):158-63. (PMID: 9420211) Virology. 2009 Sep 1;391(2):249-56. (PMID: 19584018) Curr Opin Virol. 2017 Aug;25:113-118. (PMID: 28837889) Emerg Microbes Infect. 2023 Dec;12(2):2245920. (PMID: 37542379) Cell Rep Med. 2024 Jun 18;5(6):101587. (PMID: 38781964) Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15036-41. (PMID: 12409611) Exp Mol Med. 2015 Jan 23;47:e135. (PMID: 25613732) Front Immunol. 2022 May 27;13:920467. (PMID: 35711430) EBioMedicine. 2022 Sep;83:104196. (PMID: 35932641) N Engl J Med. 2000 Aug 17;343(7):481-92. (PMID: 10944566) Lancet. 2021 Mar 6;397(10277):881-891. (PMID: 33617777) Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101. (PMID: 5242134) J Virol. 2011 Dec;85(24):13214-23. (PMID: 21957301) Joint Bone Spine. 2018 Mar;85(2):165-170. (PMID: 28499895) EBioMedicine. 2022 Aug;82:104188. (PMID: 35907368) J Virol. 2000 Nov;74(21):10142-52. (PMID: 11024143) Nat Rev Microbiol. 2021 Feb;19(2):110-121. (PMID: 33087881) Nat Med. 2003 Mar;9(3):307-14. (PMID: 12592401) Nature. 2022 Mar;603(7900):321-327. (PMID: 35073561) Nat Commun. 2016 Dec 08;7:13557. (PMID: 27929061) NPJ Vaccines. 2022 Dec 9;7(1):159. (PMID: 36494369) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Curr Top Microbiol Immunol. 2015;391:407-23. (PMID: 26428383) N Engl J Med. 2020 Dec 17;383(25):2439-2450. (PMID: 33053279) Viruses. 2022 Oct 27;14(11):. (PMID: 36366470) Elife. 2022 Feb 22;11:. (PMID: 35191378) J Virol. 1988 Apr;62(4):1108-14. (PMID: 2831373) Viruses. 2022 Jan 30;14(2):. (PMID: 35215889) |
معلومات مُعتمدة: | T32 AI007509 United States AI NIAID NIH HHS; P30 CA015704 United States CA NCI NIH HHS; 5T32AI007509 Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID); R01 CA285227 United States CA NCI NIH HHS; R01CA285227 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI); R01 AI147846 United States AI NIAID NIH HHS; R01AI147846 Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID); P30 AI027757 United States AI NIAID NIH HHS |
تواريخ الأحداث: | Date Created: 20240626 Latest Revision: 20240629 |
رمز التحديث: | 20240629 |
مُعرف محوري في PubMed: | PMC11208421 |
DOI: | 10.1038/s41541-024-00907-y |
PMID: | 38926438 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2059-0105 |
---|---|
DOI: | 10.1038/s41541-024-00907-y |